Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

PHASE3UnknownINTERVENTIONAL
Enrollment

20,426

Participants

Timeline

Start Date

November 14, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

February 28, 2022

Conditions
Ebola Virus Disease
Interventions
BIOLOGICAL

Ad26.ZEBOV, MVA-BN-Filo vaccine

"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."

Trial Locations (1)

Unknown

L'Institut National de Recherche Biomédicale RDC, Kinshasa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Epicentre

OTHER

collaborator

Ministère de la Santé de la RDC

UNKNOWN

collaborator

Médecins Sans Frontières, France

OTHER

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

Janssen Vaccines & Prevention B.V.

INDUSTRY

collaborator

Public Health England

OTHER_GOV

lead

London School of Hygiene and Tropical Medicine

OTHER